High5 Immunology TV: ECCO 2022

Therapeutic Concepts: Discussions

RESTORE-UC

ECCO 2022

Microbiota manipulation: Still a lot to learn

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

EARNEST, DIVERGENCE 2

ECCO 2022

Light at the end of the Pouchitis track

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

VEGA

ECCO 2022

Combination trials open a new door in IBD treatment

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SPARE

ECCO 2022

Is the continuation of combination therapy the key to…

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SELECTION, GALAXI 1, LUCENT-1

ECCO 2022

Combined endpoints as new therapy goals

F. Magro, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

SERENITY

ECCO 2022

The potential of histology in Crohn´s disease and how…

F. Magro, S. Danese, A. Moschen, A. Dignaß, I. Dotan, F. Gomollón, S. Schreiber

Therapeutic Concepts – ENG

SPARE

ECCO 2022

Is stopping of therapy an option in CD?

Gerhard Rogler, MD

SPARE

ECCO 2022

Infliximab withdrawl leeds to a higher risk of…

James Lindsay, MD

RESTORE-UC

ECCO 2022

A negative control trial for FMT in UC

David Laharie, MD

NOR-DRUM B

ECCO 2022

A new opportunity for proactive TDM disease control

Massimo Claudio Fantini, MD

RESTORE-UC

ECCO 2022

FMT is not a promising option for UC patients

Gerhard Rogler, MD

ECCO 2022

Is the speedity of the steroid tapering important…

Gerassimos Mantzaris, MD

VEGA

ECCO 2022

Combination of biologics

Silvio Danese, MD

VEGA

ECCO 2022

Combination of biologics - finally arrived in IBD!?

Alexander Moschen, MD

SPARE

ECCO 2022

When to withdraw therapy in crohn's disease?

Axel Dignaß, MD

SEAVUE / STARDUST

ECCO 2022

Ustekinumab for fistulizing disease

Peter Irving, MD

ECCO 2022

The interleukin-17 conundrum

Alexander Moschen, MD

VEGA

ECCO 2022

Will we improve the management of IBD by combining…

Matthieu Allez, MD

VEGA

ECCO 2022

Combination with different classes of drugs in moderate…

Fernando Magro, MD

NOR-DRUM B

ECCO 2022

Proactive TDM or SOC for monitoring infliximab…

Gerassimos Mantzaris, MD

NOR-DRUM B

ECCO 2022

Proactive TDM

Peter Irving, MD

DIVERGENCE 2

ECCO 2022

Filgotinib for fistulizing disease

Peter Irving, MD

SPARE

ECCO 2022

Withdrawal of infliximab or anti-metabolite therapy in…

Fernando Magro, MD

RESTORE-UC

ECCO 2022

FMT in UC - still far away from the success story

Piotr Eder, MD

VEGA

ECCO 2022

The first combination therapy trial

Massimo Claudio Fantini, MD

SPARE

ECCO 2022

SPARE study in ECCO 2022

Iris Dotan, MD

SPARE

ECCO 2022

How to deescalate treatment in CD?

David Laharie, MD

Therapeutic Concepts – ITA/GER/AUT/GRE/FRA/POL/ISR/SUI

SPARE

ECCO 2022

מחקר SPARE ב ECCO 2022

Iris Dotan, MD

ECCO 2022

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…

Gerassimos Mantzaris, MD

VEGA

ECCO 2022

Combinazione di biologici

Silvio Danese, MD

NOR-DRUM B

ECCO 2022

Una nuova opportunità per i TDM nel controllo proattivo…

Massimo Claudio Fantini, MD

SPARE

ECCO 2022

Wann Beendigung von Infliximab oder Immunmodulatoren…

Axel Dignaß, MD

RESTORE-UC

ECCO 2022

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Piotr Eder, MD

VEGA

ECCO 2022

Allons nous améliorer la prise en charge des MICI en…

Matthieu Allez, MD

VEGA

ECCO 2022

Kombination von Biologika - endlich bei IBD…

Alexander Moschen, MD

SPARE

ECCO 2022

Ist der Therapiestopp eine Option in CD?

Gerhard Rogler, MD

RESTORE-UC

ECCO 2022

FMT ist kein vielversprechender Ansatz für UC-Patienten

Gerhard Rogler, MD

NOR-DRUM B

ECCO 2022

Προληπτική μέτρηση των θεραπευτικών επιπέδων του…

Gerassimos Mantzaris, MD

ECCO 2022

Das Interleukin-17 Rätsel

Alexander Moschen, MD

VEGA

ECCO 2022

Il primo trial di terapia biologica di combinazione

Massimo Claudio Fantini, MD

RESTORE-UC

ECCO 2022

Un essai négatif sur la transplantation de microbiote…

David Laharie, MD

SPARE

ECCO 2022

Du nouveau sur l’allégement thérapeutique au cours de…

David Laharie, MD

Targeting Safety: Discussions